Poniard Pharmaceuticals, Inc.
Poniard Pharmaceuticals, Inc. (PARD) Revenue
Annual & quarterly revenue history · segment & region breakdown
PARD · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsPoniard Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2010.
Revenue trend
2010 – 1991 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2010-12-31 | $0.00B | +$0.00B | — |
| 2009-12-31 | $0.00B | +$0.00B | — |
| 2008-12-31 | $0.00B | +$0.00B | — |
| 2007-12-31 | $0.00B | +$0.00B | — |
| 2006-12-31 | $0.00B | -$0.00B | -100.00% |
| 2005-12-31 | $0.00B | -$0.00B | -98.52% |
| 2004-12-31 | $0.00B | -$0.01B | -90.36% |
| 2003-12-31 | $0.01B | -$0.00B | -4.73% |
| 2002-12-31 | $0.01B | +$0.01B | +284.75% |
| 2001-12-31 | $0.00B | -$0.00B | -19.05% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Poniard Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Poniard Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Poniard Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PARD revenue · 4 questionsPARD's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2010.
▸ Source: FMP · Poniard Pharmaceuticals, Inc. SEC filings · GAAP · Poniard Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026